Sermorelin, CJC-1295, and Ipamorelin: A Research Overview of Growth Hormone Peptides

Growth hormone peptides sermorelin CJC-1295 ipamorelin research Durham Peptides Canada

Among research peptide categories, growth hormone-releasing peptides occupy a distinct position. They don't directly add growth hormone to the body — instead, they act on the body's own hormone-producing machinery, modulating the natural pulsatile release pattern that the pituitary gland uses to regulate growth hormone signaling. Three compounds dominate the published research literature in this category: sermorelin, CJC-1295, and ipamorelin. Each works through a distinct receptor pathway, and the three are often discussed together because their mechanisms are complementary.

This article provides a research-focused overview of the three compounds — what each one is, how the underlying biology works, what the published preclinical and clinical literature has investigated, and how Canadian researchers should think about this peptide category. None of these compounds are currently in the Durham Peptides catalog, but they are referenced frequently in the broader peptide research literature and on educational resources like the Andrew Huberman on Peptides coverage from the Huberman Lab podcast.

The Underlying Biology: How Growth Hormone Release Works

Growth hormone (GH) is produced by the pituitary gland and released in pulses throughout the day, with the largest pulses typically occurring during deep sleep. The release is controlled by two hypothalamic peptides:

1. Growth hormone-releasing hormone (GHRH) — stimulates GH release from the pituitary.

2. Somatostatin — inhibits GH release.

The balance between these two signals creates the pulsatile pattern that characterizes natural GH release. A separate signaling pathway involves ghrelin, a peptide hormone that also stimulates GH release through a different receptor (the growth hormone secretagogue receptor, or GHSR-1a).

Growth hormone-releasing peptides in the research literature work through these natural pathways:

• Sermorelin and CJC-1295 are GHRH analogs — synthetic peptides that mimic GHRH and bind to the same receptor on pituitary cells.

• Ipamorelin is a ghrelin mimetic — a synthetic peptide that binds to the GHSR-1a receptor, the same receptor activated by ghrelin.

For the foundational overview of how peptides work in biological systems, see What Are Peptides? A Beginner's Guide to Understanding Peptide Research.

Sermorelin: The First-Generation GHRH Analog

Sermorelin is a synthetic peptide consisting of the first 29 amino acids of natural GHRH. The truncation matters: native GHRH is 44 amino acids long, but the biological activity is concentrated in the first 29. Sermorelin retains the receptor-binding activity of full-length GHRH while being shorter and easier to manufacture.

Research history. Sermorelin has the deepest clinical research history of any peptide in this category. It was developed in the 1970s and 1980s, gained FDA approval for diagnostic use in pediatric growth hormone deficiency assessment, and has been studied extensively in adult and pediatric populations.

Mechanism. Sermorelin binds to the GHRH receptor on pituitary somatotrophs (GH-producing cells), stimulating endogenous GH release in a pulsatile pattern that resembles natural physiology.

Half-life. Very short — approximately 10-20 minutes. This short half-life is intentional. It produces a brief, pulsatile signal that mimics the natural rhythm of GHRH release rather than continuously stimulating the pituitary. For more on why short half-lives can be biologically appropriate rather than a limitation, see Peptide Half-Life Explained: Why Some Peptides Last Hours and Others Days.

Research applications. Sermorelin has been studied in the context of pediatric growth hormone evaluation, adult GH deficiency research, sleep-phase hormone release, and broader endocrine function research.

CJC-1295: The Long-Acting GHRH Analog

CJC-1295 is a modified GHRH analog designed specifically to address sermorelin's short half-life. Two variants exist in the research literature:

CJC-1295 without DAC (also called Modified GRF 1-29 or "Mod GRF"). A 30-amino-acid peptide with several stabilizing modifications that resist enzymatic degradation. Half-life of approximately 30 minutes — modestly longer than sermorelin but still short enough to preserve the pulsatile release pattern.

CJC-1295 with DAC (Drug Affinity Complex). Adds a chemical modification that allows the peptide to bind reversibly to albumin in the bloodstream, dramatically extending half-life. Reported half-life of approximately 6-8 days, similar in extension strategy to the fatty-acid-conjugated GLP-1 peptides discussed in Retatrutide vs Tirzepatide vs Semaglutide.

Mechanism. Like sermorelin, CJC-1295 binds the GHRH receptor and stimulates endogenous GH release. The longer half-life of CJC-1295 with DAC produces a different pattern: instead of brief pulses, it provides sustained GHRH receptor stimulation. This is a meaningful pharmacological distinction, and the research literature treats short-acting (no DAC) and long-acting (with DAC) versions as functionally different compounds.

Research history. CJC-1295 has been studied in pharmacokinetic and endocrine research literature since the early 2000s. Clinical research is less extensive than sermorelin's, reflecting its more recent development.

The pulsatile vs. sustained release debate. The two CJC-1295 versions illustrate a recurring question in growth hormone peptide research: does pulsatile release more closely resembling natural physiology produce different biological outcomes than sustained release? The research literature has investigated both approaches, and the answers continue to develop.

Ipamorelin: The Selective Ghrelin Mimetic

Ipamorelin is a synthetic pentapeptide (5 amino acids) that mimics ghrelin's action on the GHSR-1a receptor. Its development reflected a specific research goal: producing GH release through the ghrelin pathway without the appetite-stimulating effects associated with native ghrelin or earlier ghrelin mimetics.

Mechanism. Ipamorelin binds the GHSR-1a receptor on pituitary somatotrophs, stimulating GH release through a pathway distinct from GHRH. Because GHRH and ghrelin pathways are complementary (they both stimulate GH but through different mechanisms), researchers have studied combined GHRH-analog + ghrelin-mimetic protocols to investigate additive or synergistic effects.

Selectivity. A key feature of ipamorelin in the research literature is its reported selectivity — it activates the GHSR-1a receptor with relatively limited effects on other ghrelin-responsive systems compared to earlier ghrelin mimetics.

Half-life. Approximately 2 hours — short enough to support pulsatile signaling patterns, longer than sermorelin or CJC-1295 (no DAC).

Research history. Ipamorelin has been studied in published preclinical and clinical research literature since the late 1990s. As with CJC-1295, the clinical research base is smaller than sermorelin's.

Why These Three Are Often Studied Together

Sermorelin, CJC-1295, and ipamorelin are frequently discussed as a category because their mechanisms are complementary rather than redundant:

• Sermorelin and CJC-1295 activate the GHRH receptor — the natural "release" signal pathway.

• Ipamorelin activates the GHSR-1a receptor — the ghrelin-responsive pathway.

Combined research protocols typically pair a GHRH analog (sermorelin or CJC-1295) with ipamorelin to engage both pathways simultaneously. The published literature on combined protocols investigates whether the dual-pathway approach produces additive effects compared to single-pathway protocols.

This combination logic is similar in spirit to the multi-mechanism formulations elsewhere in peptide research — for example, the GLOW Blend's three-peptide composition covers three distinct biological pathways (GHK-Cu for gene expression, BPC-157 for tissue repair, TB-500 for cell migration) in a single formulation. The growth hormone peptide category applies the same logic to the GH-release axis.

Regulatory Status in Canada and the United States

The regulatory status of growth hormone peptides is more complex than the broader research peptide category and warrants specific attention.

Sermorelin has had FDA approval for diagnostic use in pediatric GH deficiency assessment. The approved diagnostic product was withdrawn from the US market in the early 2000s, though sermorelin has continued to be available through US compounding pharmacies. The compounding pathway has been the subject of ongoing FDA scrutiny — see FDA Peptide Reclassification 2026: What It Means for Canadian Researchers for the broader regulatory context.

CJC-1295 and ipamorelin do not have FDA approval for any therapeutic indication in the United States. Both have been the subject of ongoing FDA Pharmacy Compounding Advisory Committee discussions, and both face a complicated US regulatory status.

In Canada, these compounds are not approved by Health Canada for human or veterinary therapeutic use. Research peptide framing applies — they are sold (when sold) for laboratory and research use only, not for therapeutic administration.

Durham Peptides does not currently stock sermorelin, CJC-1295, or ipamorelin. This article is informational coverage of the published research literature for Canadian researchers following the broader peptide field.

What the Research Literature Has Investigated

The published research literature on growth hormone peptides spans several investigation areas. These are research observations from the published literature, not endorsements or therapeutic claims:

Endogenous GH pulsatility research. How GHRH analogs and ghrelin mimetics affect the natural pulsatile pattern of GH release, and what biological consequences different patterns produce.

Sleep-phase hormone release research. GH's connection to deep sleep stages has made the growth hormone peptide category a focus of sleep research. Sermorelin in particular has been studied for its effects on sleep architecture in research populations.

Metabolic and body composition research. Long-term effects of GH axis modulation on metabolism, lean mass, and adiposity have been studied across both pediatric and adult research populations.

Aging and endocrine research. Natural GH release declines with age in both clinical research populations. The GH axis has been an area of investigation in aging research, though the relationship between supplemental GH-releasing peptide research and aging biology remains complex and incompletely understood.

Combination protocol research. As discussed above, combined GHRH-analog + ghrelin-mimetic protocols have been investigated for whether dual-pathway activation produces different outcomes than single-pathway protocols.

The Growth Hormone Peptide Research Category vs. the Broader Catalog

How the growth hormone peptide category fits into the broader research peptide landscape:

Distinct mechanism from tissue-repair peptides. BPC-157 and TB-500 work through tissue-localized pathways (angiogenesis, cell migration, growth factor modulation). Growth hormone peptides work systemically through the hypothalamic-pituitary axis. Different research questions, different mechanisms.

Distinct mechanism from metabolic peptides. Semaglutide, tirzepatide, and retatrutide work through incretin receptor pathways unrelated to GH. The research questions and biological pathways are entirely separate.

Some overlap with anti-aging peptide research. GH axis biology is relevant to broader aging research questions, which connects loosely to the anti-aging peptide research literature on GHK-Cu and MOTS-c. The mechanisms differ but the research conversation overlaps.

Quality Control Considerations

Whether or not Durham Peptides eventually carries growth hormone peptides, the quality control framework for any research peptide in this category should match the framework applied across the broader catalog:

• Independent third-party testing via Janoshik Analytical with verifiable unique key

• ≥99% HPLC purity with mass spectrometry identity confirmation

• Solid-Phase Peptide Synthesis manufacturing with no animal-derived materials

• Clear research-use-only framing

For the complete framework, see 5 Things to Look for in a Canadian Peptide Supplier and Peptides for Sale in Canada: A Researcher's Supplier Directory.

Frequently Asked Questions

What are growth hormone peptides? Synthetic peptides that act on the body's natural growth hormone release pathways — either by mimicking growth hormone-releasing hormone (GHRH) or by mimicking ghrelin. They do not directly contain growth hormone.

What's the difference between sermorelin, CJC-1295, and ipamorelin? Sermorelin and CJC-1295 are GHRH analogs (act on the GHRH receptor). Ipamorelin is a ghrelin mimetic (acts on the GHSR-1a receptor). The two pathways are complementary rather than redundant.

What is CJC-1295 with DAC vs without DAC? "DAC" stands for Drug Affinity Complex. With DAC, CJC-1295 has a half-life of approximately 6-8 days. Without DAC, the half-life is approximately 30 minutes. The two versions are functionally different compounds in research applications.

Are growth hormone peptides FDA-approved? Sermorelin had historical FDA approval for diagnostic use in pediatric GH deficiency assessment (subsequently withdrawn from the US market). CJC-1295 and ipamorelin do not have FDA approval for therapeutic indications. All three are subject to ongoing US regulatory discussions.

Are growth hormone peptides approved in Canada? No. None of these compounds are approved by Health Canada for human or veterinary therapeutic use. They are not in the Durham Peptides catalog and are referenced in this article for educational research context only.

Does Durham Peptides sell sermorelin? No. Durham Peptides does not currently stock sermorelin, CJC-1295, or ipamorelin. Our current catalog includes BPC-157, TB-500, GHK-Cu, MOTS-c, semaglutide, tirzepatide, retatrutide, the GLOW Blend, the Wolverine Stack, and bacteriostatic water.

Why do researchers combine GHRH analogs and ipamorelin? Because the two pathways are complementary. GHRH analogs activate the GHRH receptor; ipamorelin activates the GHSR-1a (ghrelin) receptor. Combined research protocols engage both pathways to investigate whether dual-pathway activation produces different outcomes than single-pathway activation.

What's the half-life of these growth hormone peptides? Sermorelin: approximately 10-20 minutes. CJC-1295 (without DAC): approximately 30 minutes. CJC-1295 (with DAC): approximately 6-8 days. Ipamorelin: approximately 2 hours.

Are growth hormone peptides anti-aging peptides? The GH axis is relevant to broader aging research, but the mechanism is distinct from the anti-aging peptide research on compounds like GHK-Cu and MOTS-c. They overlap loosely in research interest but operate through different biological pathways.

Is there published clinical research on these peptides? Yes. Sermorelin has the deepest clinical research base, including pediatric GH deficiency studies. CJC-1295 and ipamorelin have substantial preclinical research and more limited clinical research. See the Selected Research References at the end of this article.

Are growth hormone peptides the same as HGH? No. HGH (human growth hormone) is the actual GH hormone — recombinantly produced in pharmaceutical form and dispensed under prescription for approved indications. Growth hormone peptides like sermorelin, CJC-1295, and ipamorelin are not GH itself; they act on the body's own GH-producing pathway.

Final Thoughts

The growth hormone peptide research category — sermorelin, CJC-1295, and ipamorelin — represents a distinct branch of peptide research that operates through the hypothalamic-pituitary axis rather than through tissue-repair or metabolic pathways. The category has a substantial published research literature, ongoing regulatory considerations, and a complementary multi-pathway logic that has shaped how research protocols are designed.

For Canadian researchers, these compounds are not currently in the Durham Peptides catalog. Researchers seeking products in this category will need to evaluate other suppliers using the same six-criteria framework — Janoshik-verified third-party testing, ≥99% HPLC purity, mass spectrometry identity confirmation, SPPS synthetic manufacturing, transparent Canadian-dollar pricing, and research-use-only framing. See 5 Things to Look for in a Canadian Peptide Supplier for the supplier evaluation framework.

For the broader Canadian peptide market context, see The Canadian Peptide Market in 2026: What Researchers Should Know. For the regulatory framework affecting peptide research more broadly, see FDA Peptide Reclassification 2026: What It Means for Canadian Researchers.

Browse the complete Durham Peptides catalog at durhampeptides.ca/category/all-products.

Selected Research References

1. Walker RF, Eichler DC, Bercu BB. Inadequate Pituitary Stimulation: A Possible Cause of Growth Hormone Insufficiency and Hyperprolactinemia in Women. Endocrine. 1996;5(3):225-230. https://pubmed.ncbi.nlm.nih.gov/21153075/

2. Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged Stimulation of Growth Hormone (GH) and Insulin-like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults. Journal of Clinical Endocrinology & Metabolism. 2006;91(3):799-805. https://pubmed.ncbi.nlm.nih.gov/16352683/

3. Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the First Selective Growth Hormone Secretagogue. European Journal of Endocrinology. 1998;139(5):552-561. https://pubmed.ncbi.nlm.nih.gov/9849822/

4. Sinha DK, Balasubramanian A, Tatem AJ, et al. Beyond the Androgen Receptor: The Role of Growth Hormone Secretagogues in the Modern Management of Body Composition in Hypogonadal Males. Translational Andrology and Urology. 2020;9(Suppl 2):S149-S159. https://pubmed.ncbi.nlm.nih.gov/32257855/

5. Khorram O, Laughlin GA, Yen SS. Endocrine and Metabolic Effects of Long-Term Administration of [Nle27]Growth Hormone-Releasing Hormone-(1-29)-NH2 in Age-Advanced Men and Women. Journal of Clinical Endocrinology & Metabolism. 1997;82(5):1472-1479. https://pubmed.ncbi.nlm.nih.gov/9141537/

6. Bowers CY. Growth Hormone-Releasing Peptide (GHRP). Cellular and Molecular Life Sciences. 1998;54(12):1316-1329. https://pubmed.ncbi.nlm.nih.gov/9893706/

All products sold by Durham Peptides are for research and laboratory use only. They are not intended for human or animal consumption, diagnosis, treatment, cure, or prevention of any disease. This article is informational coverage of published research literature on compounds not currently stocked by Durham Peptides. Readers seeking medical guidance should consult a licensed healthcare provider.